UK Markets close in 3 hrs 33 mins

Alzamend Neuro, Inc. (ALZN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9104-0.0187 (-2.01%)
At close: 04:00PM EDT
0.9300 +0.02 (+2.15%)
Pre-market: 07:33AM EDT

Alzamend Neuro, Inc.

3500 Lenox Road NE
Suite 1500
Atlanta, GA 30326
United States
844 722 6333

Full-time employees3

Key executives

NameTitlePayExercisedYear born
Mr. Stephan JackmanCEO & Director225kN/A1976
Mr. Henry C. W. Nisser Esq.Exec. VP, Gen. Counsel & Director50kN/A1969
Mr. Kenneth S. Cragun CPASr. VP of Fin.100kN/A1961
Mr. Milton Charles Ault IIIFounder & Chairman EmeritusN/AN/A1970
Ms. Lien T. EscalonaChief Financial OfficerN/AN/A1969
Mr. David J. KatzoffChief Operating OfficerN/AN/A1962
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Corporate governance

Alzamend Neuro, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.